October 3, 2024

48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia

Key Points

Key points are not available for this paper at this time.

Abstract

We previously demonstrated at the Ward 86 HIV clinic in San Francisco that long-acting cabotegravir/rilpivirine (LA-CAB/RPV) can rapidly lead to viral suppression (VS) in people with HIV (PWH) with viremia due to adherence challenges. We now evaluate VS durability in this population.

Bookmark

Cite This Study

Hickey et al. (Thu,) studied this question.

synapsesocial.com/papers/68e55db1e2b3180350efafd9 https://doi.org/https://doi.org/10.1093/cid/ciae500

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel2024 · 51 citations
2Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis2024 · 52 citations
3<i>Letter to the Editor:</i> Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report2024 · 5 citations
41028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort2023 · 20 citations
5Latent Class Analysis of Syndemic Factors Associated with Sustained Viral Suppression among Ryan White HIV/AIDS Program Clients in Miami, 20172021 · 8 citations

Bookmark